Codexis, Inc.

Greetings and welcome to the Codex's second quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow a formal presentation. If anyone should require operator assistance during the conference, press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Georgia Erbez, Chief Financial Officer and Chief Business Officer. Thank you. You may begin.

Thank you, Operator. With me today are Alison Moore, President and Chief Executive Officer, Stefan Lutz, Chief Scientific Officer, and Britton Jimenez, Senior Vice President, Sales and Marketing. During this call, management will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our guidance for 2026 revenue, anticipated milestones and product launches, facility expansions, technical milestones, and public announcements related thereto, as well as our strategies and prospects for revenue growth, path to profitability, and successful execution of current and future programs and partnerships. To the extent that statements contained in this call are not descriptions of historical facts regarding Codexys, They are forward-looking statements reflecting the beliefs and expectations of management as of the statement date, August 11, 2026. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors that are, in some cases, beyond Codexys' control that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codexys filings with the Securities and Exchange Commission. Codexys expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. And now I'll turn the call over to Alison.

Thank you, Georgia, and thanks everyone for joining. Codexis generates manufacturing solutions using high performance engineered enzymes. The investment of over 20 years of our expertise is playing out in our pharma biocatalysis pipeline, which supports 14 commercial products and a pipeline of 15 in phase two and three clinical development. This expertise has also enabled the creation of the Ecosynthesis manufacturing platform A scalable, aqueous process for the production of oligonucleotides. I'm pleased to share our progress through the first half of 2026, and I'm excited for the rest of the year and beyond. Today, we reported solid financial results for the second quarter of 2026 with revenue of $14.9 million. Our recent successful financing, which closed two weeks ago, resulted in a capital raise of $25 million of net proceeds. This provides us with greater stability and flexibility as we pursue our strategic goals. Georgia will give us more details on our financial achievements later in the call. An important highlight of the quarter was the Tides U.S. conference in May. where we shared important new data on our ecosynthesis technology. Codexys presented data demonstrating full-length siRNA synthesis with precise control of phosphorothioate chemistry using our technology platform. Stereochemistry plays an important role in how oligonucleotides perform. Stefan Lutz, our Chief Scientific Officer, will provide additional details on the growing capabilities of our platform later in the call. I'm also pleased to report that the construction of our GMP manufacturing facility is proceeding according to plan. This facility is a core component of our strategy to enable the adoption of ecosynthesis into the pipelines and supply chains of our customers. This facility will deliver GMP material to support IND filings and supply clinical trials and deepen Codex's production scale platform expertise. Our building permit application will be submitted momentarily and our manufacturing equipment has been ordered. We will begin construction following approval of the permit. The cost of the construction for this project is approximately $25 million. This investment underscores our long-term commitment to supporting product development, scale-up, and manufacturing for our customers. Years ago, the pioneering science of codexes transformed the opportunities available to process chemists, enabling the manufacture of complex small molecule chemistries. This innovation has now become standard practice in the production of small molecule medicines. Today, we believe that the Ecosynthesis platform will similarly revolutionize the ability to generate large-scale quantities of siRNA medicines, making this advanced modality accessible to patients across all therapeutic areas. Ecosynthesis, which leverages enzymatic production solutions offers a scalable alternative to the current solid-phase organic synthesis technology. The latter is not sufficiently scalable and requires enormous quantities of solvent, posing significant challenges, as demand for siRNA is expected to increase 30-fold by 2035. This manufacturing bottleneck is anticipated to emerge within the next three years particularly as large phase III cardiovascular trials reach their conclusions. As communicated at TIDES, the industry recognizes the limitations of current production methods and acknowledges the need for radical new technologies. The impact of the ecosynthesis platform is becoming increasingly clear as more organizations embrace enzymatic approaches. Codexis is in the leading position to industrialize this important new method. I will now turn the call over to Stefan for more details on our TIDES data.